Achiko AG (ACHKF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Achiko AG (ACHKF) stock?
Achiko AG (ACHKF) no longer trades on public markets. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Achiko AG (ACHKF). Achiko AG is a healthcare company focused on developing diagnostic solutions, including the AptameX rapid Covid-19 test and the Teman Sehat mobile application. The company also provides payment solutions and develops game software. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for ACHKF: ACHKF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACHKF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ACHKF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Achiko AG (ACHKF) Healthcare & Pipeline Overview
Achiko AG is a Swiss-based healthcare company specializing in disruptive diagnostic solutions, including the AptameX rapid COVID-19 test utilizing DNA aptamers. The company also offers the Teman Sehat mobile health passport and Mimopay, a secure payment platform for digital content, operating primarily in Indonesia and internationally.
What Is the Investment Thesis for ACHKF?
Achiko AG presents a high-risk, high-reward investment opportunity in the healthcare and digital solutions space. The company's AptameX rapid COVID-19 test offers potential as a disruptive diagnostic tool, although its market acceptance and regulatory approvals remain uncertain. The Teman Sehat mobile application could gain traction as a health passport solution, particularly in regions with evolving public health requirements. However, Achiko's financial performance, characterized by a negative profit margin of -14913.2% and a small market capitalization, indicates significant challenges. The company's success hinges on its ability to successfully commercialize its products, secure funding, and navigate a competitive landscape. Investors should carefully consider the risks associated with Achiko's OTC listing and limited financial disclosure.
Based on FMP financials and quantitative analysis
ACHKF Key Highlights
Achiko AG operates with a small team of 10 employees, indicating a lean operational structure.
- The company's lead product, AptameX, is a rapid test for SARS-CoV-2 using DNA aptamers, potentially offering a faster and more cost-effective diagnostic solution.
- Achiko's gross margin stands at 37.3%, reflecting the potential profitability of its diagnostic and digital solutions.
- The company's negative P/E ratio of -0.04 and profit margin of -14913.2% highlight its current financial challenges.
- Achiko AG's beta of -0.39 suggests a low correlation with the overall market, potentially offering some diversification benefits.
Who Are ACHKF's Competitors?
ACHKF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MGRX Mangoceuticals, Inc. | $0.39 | +1.51% | $6.63M | — |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.49 | -1.32% | $9.00M | — |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | — |
| SCNX Scienture Holdings, Inc. | $0.35 | -2.69% | $14.1M | — |
| BEAT HeartBeam, Inc. | $0.40 | -2.14% | $22.3M | — |
| EUDA EUDA Health Holdings Limited | $13.12 | +0.15% | $24.5M | — |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | — |
| ONMD OneMedNet Corporation | $0.67 | -1.84% | $38.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACHKF's Key Strengths?
Innovative AptameX technology for rapid COVID-19 testing.
- Teman Sehat mobile app addresses the need for digital health solutions.
- Mimopay provides a secure payment platform for digital content.
- Geographic focus on Indonesia and international markets.
What Are ACHKF's Weaknesses?
Limited financial resources and small market capitalization.
- Negative profit margin and reliance on external funding.
- OTC listing with limited liquidity and disclosure requirements.
- Dependence on the success of a few key products.
What Could Drive ACHKF Stock Higher?
Regulatory approvals for AptameX in key markets, potentially expanding its commercial reach.
- Strategic partnerships with healthcare providers or distributors to increase AptameX sales.
- Continued adoption of Teman Sehat mobile app by organizations and government agencies.
- Expansion of Mimopay payment solutions to new digital content providers.
- Development of new diagnostic tests based on the AptameX technology.
What Are the Key Risks for ACHKF?
Financial-distress signal — its Altman Z-Score of -44.85 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established healthcare companies and diagnostic providers.
- Regulatory hurdles and delays in obtaining approvals for AptameX.
- Changes in public health policies and testing requirements.
- Limited financial resources and reliance on external funding.
- OTC listing with limited liquidity and disclosure requirements.
What Are the Growth Opportunities for ACHKF?
- Expansion of AptameX Testing: Achiko has the opportunity to expand the market reach of its AptameX rapid COVID-19 test. The global market for COVID-19 diagnostics is expected to remain substantial, driven by ongoing testing needs and the emergence of new variants. Securing regulatory approvals in key markets and establishing distribution partnerships could significantly increase AptameX sales. The timeline for this growth opportunity is ongoing, as the pandemic continues to evolve and testing remains a critical tool for managing its spread.
- Adoption of Teman Sehat Mobile App: Achiko can capitalize on the growing demand for digital health solutions by promoting its Teman Sehat mobile application. As governments and organizations seek ways to manage public health and facilitate safe travel, Teman Sehat could gain traction as a health passport and check-in system. Partnering with airlines, event organizers, and government agencies could accelerate adoption. The timeline for this growth opportunity is near-term, as the need for digital health solutions persists.
- Diversification of Diagnostic Solutions: Achiko can leverage its AptameX technology to develop diagnostic tests for other infectious diseases and health conditions. Expanding its product portfolio beyond COVID-19 would reduce its reliance on a single market and create new revenue streams. The global diagnostics market is vast and growing, offering numerous opportunities for innovative testing solutions. The timeline for this growth opportunity is medium-term, as it requires research, development, and clinical validation.
- Strategic Partnerships and Acquisitions: Achiko can accelerate its growth by forming strategic partnerships with established healthcare companies or acquiring complementary businesses. Collaborations with larger players could provide access to wider distribution networks, regulatory expertise, and financial resources. Acquisitions could expand Achiko's product portfolio and technological capabilities. The timeline for this growth opportunity is ongoing, as Achiko continuously seeks opportunities to enhance its competitive position.
- Expansion of Mimopay Payment Solutions: Achiko can expand its Mimopay payment solutions to serve a wider range of digital content providers and application developers. The global market for digital payments is experiencing rapid growth, driven by the increasing adoption of online gaming, e-commerce, and mobile applications. By offering secure and convenient payment options, Mimopay can attract new customers and increase its transaction volume. The timeline for this growth opportunity is medium-term, as it requires ongoing investment in technology and marketing.
What Are ACHKF's Competitive Advantages?
- Proprietary AptameX technology using DNA aptamers for rapid diagnostics.
- First-mover advantage in developing a mobile health passport solution with Teman Sehat.
- Established relationships with game publishers and application developers through Mimopay.
- Geographic focus on Indonesia and international markets with specific local expertise.
What Does ACHKF Do?
Achiko AG, incorporated in 2018 and headquartered in Zurich, Switzerland, is a healthcare company focused on developing and commercializing disruptive diagnostic solutions. The company's primary focus is on its AptameX technology, a rapid diagnostic test for the SARS-CoV-2 virus that utilizes DNA aptamers instead of traditional antibodies. This innovative approach aims to provide a faster and potentially more cost-effective testing solution. In addition to AptameX, Achiko offers Teman Sehat, a mobile application designed as a health passport and check-in system, particularly relevant in the context of pandemic management and public health monitoring. Beyond diagnostics, Achiko AG also operates Mimopay, a secure payment solution tailored for game publishers and application developers. Mimopay enables these businesses to accept a wide range of payment methods for digital content and goods. The company also engages in game software development, diversifying its revenue streams and leveraging its technological capabilities. Achiko's operations are primarily based in Indonesia and internationally, reflecting its strategy to address global healthcare and digital payment needs. The company's relatively small size, with approximately 10 employees, suggests a focus on strategic partnerships and efficient resource allocation to achieve its goals.
What Products and Services Does ACHKF Offer?
- Develops the AptameX rapid test for detecting the SARS-CoV-2 virus using DNA aptamers.
- Offers the Teman Sehat mobile application for health passport and check-in functionalities.
- Provides Mimopay, a secure payment solution for game publishers and application developers.
- Enables acceptance of various payment methods for digital content and goods.
- Engages in game software development.
- Focuses on disruptive diagnostic solutions in Indonesia and internationally.
How Does ACHKF Make Money?
- Generates revenue from the sale of AptameX rapid COVID-19 tests.
- Offers Teman Sehat as a subscription or licensing model for organizations and governments.
- Earns transaction fees from Mimopay payment processing for digital content and goods.
- Derives income from the sale of game software.
What Industry Does ACHKF Operate In?
Achiko AG operates within the healthcare information services industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for efficient diagnostic and digital health solutions. The COVID-19 pandemic has accelerated the adoption of rapid testing and mobile health applications, creating opportunities for companies like Achiko. However, the industry is also highly competitive, with established players such as ALSE (Alseres Pharmaceuticals), AQQRF (AdvanCell Isotopes), FLURF (Flora Growth Corp), LNDZF (Landa App), and MSITF (MITS Inc) and numerous startups vying for market share. Achiko's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strategic partnerships.
Who Are ACHKF's Key Customers?
- Healthcare providers and testing centers using AptameX for rapid COVID-19 detection.
- Organizations and government agencies implementing Teman Sehat for health monitoring and check-in.
- Game publishers and application developers utilizing Mimopay for secure payment processing.
- Consumers purchasing game software developed by Achiko.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 46 |
| 2026-08-24 | 46 |
| 2026-08-25 | 46 |
| 2026-08-26 | 46 |
What changed?
The score has stayed at 46.
Over the same 3 days the stock moved +0.0%.
Financial Health
Achiko AG's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -44.85 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Achiko AG stands at 215.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.35 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Achiko AG operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Zurich, CH. The company is led by CEO Wern-Yi Goh. ACHKF has traded publicly since 2021.
ACHKF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative AptameX technology for rapid COVID-19 testing.
- Teman Sehat mobile app addresses the need for digital health solutions.
- Mimopay provides a secure payment platform for digital content.
- Geographic focus on Indonesia and international markets.
Bear Case
- Limited financial resources and small market capitalization.
- Negative profit margin and reliance on external funding.
- OTC listing with limited liquidity and disclosure requirements.
- Dependence on the success of a few key products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ACHKF Latest News
No recent news available for ACHKF.
Leadership: Wern-Yi Goh
Managing
Wern-Yi Goh serves as Managing for Achiko AG, overseeing the company's strategic direction and operations. His background includes experience in managing small teams, as Achiko AG currently has 10 employees. However, his leadership is crucial for guiding Achiko AG through its development and commercialization efforts in the healthcare and digital solutions space.
Track Record: Due to limited information, Wern-Yi Goh's specific achievements and strategic decisions at Achiko AG cannot be comprehensively assessed. However, under his management, the company has focused on developing and promoting its AptameX rapid COVID-19 test, Teman Sehat mobile application, and Mimopay payment solutions. The success of these initiatives will be key to evaluating his long-term track record.
ACHKF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Achiko AG may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in ACHKF.
- OTC Tier: OTC Other
- Limited liquidity and wider bid-ask spreads compared to major exchanges.
- Lack of regulatory oversight and potential for fraud or manipulation.
- Unknown disclosure status and limited availability of financial information.
- Greater price volatility and susceptibility to market rumors.
- Potential for delisting or suspension of trading.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements (if available).
- Assess the company's management team and their track record.
- Research the company's products, services, and market position.
- Evaluate the company's competitive landscape and potential risks.
- Understand the company's capital structure and funding requirements.
- Consult with a qualified financial advisor before investing.
- Company is incorporated in Switzerland, a jurisdiction with established corporate governance standards.
- Achiko AG has a registered business address and contact information.
- The company is actively developing and marketing its products and services.
- Achiko AG has a website and social media presence.
- The company has announced partnerships and collaborations with other organizations.
Achiko AG Healthcare Stock: Key Questions Answered
What happened to Achiko AG (ACHKF) stock?
Achiko AG (ACHKF) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy ACHKF shares?
No. ACHKF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for ACHKF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ACHKF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Achiko AG. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Achiko AG do?
Achiko AG is a healthcare company focused on developing and commercializing disruptive diagnostic and digital solutions. Its primary product is AptameX, a rapid test for detecting the SARS-CoV-2 virus using DNA aptamers. The company also offers Teman Sehat, a mobile application designed as a health passport and check-in system.
What do analysts say about ACHKF stock?
As of 2026-03-16, formal analyst coverage of ACHKF is limited due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to the company's financial challenges.
What are the main risks for ACHKF?
The main risks for ACHKF include its limited financial resources, reliance on external funding, and OTC listing with limited liquidity and disclosure requirements. Changes in public health policies and testing requirements could also impact the demand for its products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete.
- OTC market data may be less reliable than major exchange data.